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Research over the past two decades has elucidated the molecular mechanisms underlying ErbB-
induced tumorigenesis, which has resulted in the development of effective targeted therapies.
ErbB-induced signal transduction cascades regulate a wide variety of cell processes, including cell
proliferation, apoptosis, cell polarity, migration and invasion. Within tumors, disruption of these
core processes, through cooperative oncogenic lesions, results in aggressive, metastatic disease.
This review will focus on the ErbB signaling networks that regulate migration and invasion and
identify a potential role for cell polarity pathways during cancer progression.
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Dysregulation of oncogenes and tumor suppressors drives the
malignant processes underlying human tumors. Disruption of
normal cellular and tissue architecture and acquisition of poorly
differentiated states are frequently associated with malignancy.
How oncogenes and tumor suppressors interact with tumor cell
architecture andmicroenvironment to induce invasive activity and
metastatic spread remains largely unexplored. One of the most
widely studied families of oncogenic proteins is the human
epidermal growth factor receptor (EGFR) family. The EGFR family
of type I receptor tyrosine kinases is comprised of four members:
EGFR/HER1/ErbB1, Neu/HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4
[1]. ErbB receptors have been implicated in the initiation and
progression of various cancers, including those of the breast, ovary,
lung, stomach, brain and bladder, where ErbB amplification and
overexpression have been correlated with aggressive clinical
outcome [2–4].
Activation of the ErbB receptors is accomplished through ligand
binding to the extracellular domain, followed by receptor homo- or
heterodimerization and tyrosine transphosphorylation of the C-
terminal tail [5]. There are over 12 ligands that bind ErbB receptors
and induce dimerization of distinct functional receptor pairs.
Among these, epidermal growth factor (EGF), transforming growth
factor alpha (TGF-α), and amphiregulin (AR) selectively bind to
ErbB1 and primarily induce formation of ErbB1/ErbB1 homodi-
mers and ErbB1/ErbB2 heterodimers [6]. Betacellulin (BTC),
heparin-binding EGF (HB-EGF) and epiregulin (EPR) comprise a
second class of ligands that bind both ErbB1 and ErbB4 [7]. The
neuregulins (NRG1–4) encompass the third class of ligands and
activate ErbB3 and ErbB4 [8–10]. Currently, no known ligands have
been identified for ErbB2. However, ErbB2 is the preferred
heterodimerization partner of the other ErbB family members
and ErbB2-containing heterodimers have the strongest signaling
output [11,12]. The great diversity of ligands and receptor dimer
pairs allows the activation of numerous signaling pathways that
coordinately regulate complex processes including developmental
growth control and adult homeostasis.
In the inactive state, the extracellular domains of the ErbB
receptors exist in a closed inhibited form [13]. However, ligand
binding induces a conformational change in the extracellular
domain that allows receptor dimerization and subsequent autop-
hosphorylation of the tyrosine residues located in the cytoplasmic
tail. Interestingly, ErbB2 is constitutively present in the active state
and capable of forming heterodimers with ligand-bound ErbB1, 3
or 4 receptors for downstream signaling. ErbB3 lacks a functional
kinase domain and must be paired in a heterodimeric fashion [14].
The phosphorylated ErbB receptors serve as molecular integrators
through either direct phosphorylation of target molecules or by
serving as scaffolds for adaptor proteins [15]. Activation of ErbB
receptors leads to initiation of themitogen activated protein kinase
(MAPK) cascade, activation of phospholipase C gamma (PLCγ) and
phosphatidylinositol 3 kinase (PI3K), as well as induction of the
small GTPases Rho, Rac and Cdc42, among many other effectors
[16]. Several reports have demonstrated a role for these pathways
in ErbB-induced cell migration.
However, the interaction between ErbB signaling and cell
polarity pathways and its role in migration and invasion are poorly
understood. In polarized epithelial cells, ErbB receptors are presentin the basolateral surface, alongwith E-cadherin, gap junctions and
desmosomes [17]. ErbB receptors are neither seen in the apical
surface, containing glycoproteins and microvilli, nor in tight
junctions, containing occludins and claudins. This spatial asy-
mmetry is lost during initiation and progression of cancer, and in
particular, during metastasis. In this review we will discuss a
potential role for cell polarity pathways during progression of
ErbB-driven tumors.ErbB receptor function in cancer progression
Overexpression or mutations in ErbB receptors have been
identified in numerous human tumors and cancer cell lines [18].
ErbB1 was first cloned and its sequence determined from A431
epidermoid carcinoma cells, facilitated by its amplification and
mRNA overproduction [19–22]. Subsequent analysis has demons-
trated that ErbB1 is amplified in 40% of glioblastomas [23]. More
recently, mutations in ErbB1 have been detected in non-small cell
lung carcinomas, medulloblastomas and ovarian cancers [24,25].
Activated ErbB1 can also function as a tumor promoter through
autocrine signaling in lung, prostate and gastrointestinal stromal
tumors coexpressing TGF-α [26–28]. Kinase inhibitors (Erlotinib,
Gefitinib) and monoclonal antibodies (Cetuximab, Panitumumab)
targeting ErbB1 are currently in clinical use against non-small-cell
lung cancer, colorectal cancer, pancreatic cancer and squamous-
cell carcinoma of the head and neck [29].
Since the discovery of neu as an oncogene in a rat
carcinogen-induced tumor model in 1981 [30], several lines of
evidence demonstrate that this gene product possesses onco-
genic properties. Neu was subsequently shown to be similar to
the v-erbB oncogene from the avian erythroblastosis virus and
the mammalian EGFR [31,32]. One of the strongest pieces of
evidence for its role in cancer came from the observation that
neu is amplified in human breast and ovarian cancers and
cancer-derived cell lines [2,33]. These studies laid the foundation
for the development of targeted therapeutic strategies against
neu/ErbB2/HER2. Today, an antibody against ErbB2, Herceptin
(Trastuzumab), and a kinase inhibitor, Lapatinib (Tykerb), are
used in the clinic for the treatment of ErbB2-positive breast
cancers [34].
Several mouse models expressing neu in the mouse mam-
mary gland have allowed us to gain critical insights into the
mechanisms by which ErbB2 induces mammary tumor initiation
and progression. Expression of activated neu (neuT; a V664E
mutation that promotes spontaneous receptor dimerization) in
the mammary glands of mice under the direction of the mouse
mammary tumor virus (MMTV) promoter led to the formation
of mammary adenocarcinomas [35,36]. These mice developed
multifocal tumors involving the entire mammary gland, sugges-
ting that additional genetic changes were not required for neuT-
induced tumorigenesis. Strikingly, mice expressing wild-type neu
in the mammary epithelium developed focal mammary tumors
after long latency, with a low penetrance of lung metastasis
[37]. The presence of transgene-positive regions of normal
mammary epithelium surrounding the tumors supported the
hypothesis that overexpression of wild-type neu alone is not
sufficient for tumor development. Further investigation into the
mechanism of tumor formation in these transgenic mice showed
that additional genetic changes were necessary for tumo-
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itself [38].
In human breast cancer, amplification of ErbB2 correlates with
a decrease in time to disease relapse and overall patient survival,
with highly expressing tumors predictive of worse clinical
outcome [2]. Despite the clinical relationship between ErbB2
expression and poor patient outcome, several lines of evidence
suggest that amplification of ErbB2 is an early event in
tumorigenesis, and not solely associated with invasive disease.
As discussed previously, mouse models of wild type ErbB2 fail to
transform the entire mammary epithelium and form only focal
tumors after long latency that rarely metastasize, requiring the
acquisition of secondary genetic events. Additionally, we demons-
trated that forced dimerization of ErbB2 in three dimensional
(3D) mammary acinar structures induced proliferation and lumen
filling, but did not lead to degradation of the basement
membrane or invasive behavior [39]. More than 45% of human
non-invasive breast carcinomas can posses amplified and over-
expressed ErbB2, suggesting that additional genetic events are
required for metastatic progression of ErbB2-positive tumors [40].
It is likely that understanding the genetic and biochemical events
that cooperate with ErbB2 to induce metastatic disease will
provide novel insights to control the spread of ErbB2-positive
tumors.ErbBs regulate epithelial cell migration and invasion
The ability of growth factors of the EGF family to stimulate
epithelial cell migration has been appreciated for over 20 years. In
an early experiment, EGF was shown to stimulate migration of
untransformed small intestine cells through gelatin-coated filters
[41]. This induced movement was directional and specific for EGF
and not other growth factors. Similarly, EGF and TGF-αwere found
to increase cell migratory capacity of epidermal keratinocytes [42].
In renal carcinoma-derived cell lines, EGF can induce production of
matrix metalloproteinase-9 (MMP-9) and in vitro invasion [43]. In
addition, stimulation of glioma-derived cells with TGF-α or breast
cancer-derived cells with heregulin induces invasive progression,
suggesting that multiple EGF ligands and their receptors are likely
to be involved in metastatic disease [44,45].
ErbB receptors are also known to play critical roles during
migration and invasion of cancer-derived cell lines in vitro and in
vivo. Prostate carcinoma cells expressing ErbB1 injected into
athymic mice formed tumors that are capable of metastasizing to
the lung [46]. However, treatment of these mice with an inhibitor
of ErbB1-mediated cell motility (through inhibition of phospholi-
pase Cγ), but not proliferation, resulted in tumors with decreased
invasiveness. Similarly, inhibition of ErbB1 in a mouse model of
pancreatic cancer attenuated tumor volume and liver metastasis
through a mechanism involving inhibition of tumor-associated
angiogenesis [47]. Tumor cells with decreased ErbB1 signaling
produced fewer proangiogenic molecules, resulting in increased
endothelial cell apoptosis. In a breast cancer model utilizing
injection of mammary adenocarcinoma cells into themammary fat
pad, ErbB1 or ErbB3 overexpression was found to increase
intravasation and metastasis to the lungs, while having minimal
impact on tumor growth [48,49]. These studies have highlighted,
both in vitro and in vivo, the crucial roles of ErbB receptors in
metastatic cancer progression.Signaling pathways downstream of ErbB receptors
and cell migration
Several signaling cascades are activated in response to specific
ErbB homo- or heterodimer pairs, resulting in the cytoskeletal
reorganization and gene transcription necessary for migration and
invasion of epithelial cells [16]. These involve stimulation of PLCγ,
small G-proteins of the Ras superfamily, PI3K and Src. How these
proteins coordinately regulate epithelial cell migration and
invasion in response to ErbB activation is critically important for
understanding the metastatic process, and can lead to novel
targets for therapeutic intervention.
Control over actin dynamics allows ErbB receptors to induce
cell shape changes required for cell movement, either through
direct actin binding or modulation of actin-regulatory proteins
[50]. Upon EGF stimulation, ErbB1 phosphorylates PLCγ1, inducing
enzyme activation and subsequent production of the second
messengers inositol trisphosphate (IP3) and diacylglycerol (DAG)
from phosphatidylinositol 4,5-bisphosphate (PIP2) [51]. Inhibition
of PLC, or a dominant-negative PLCγ1 fragment attenuates EGF-
induced migration in NR6 fibroblasts demonstrating that PLCγ1
activation plays a critical role during cell migration [52]. Experi-
ments performed in invasive prostate and breast tumor cells lines
confirmed the requirement of PLCγ1 in migration, showing that
chemical inhibition of PLCγ1 reduced invasion through Matrigel
[53]. PLCγ is also involved in ErbB heterodimer-induced migration
and invasion [54]. Whereas ErbB1 and ErbB2 homodimers were
unable to induce invasion in mammary epithelial cells, dimeriza-
tion of ErbB1 and ErbB2 led to PLCγ-dependent invasion. The
hydrolysis of PIP2 allows dissociation of several actin-binding
proteins from the plasmamembrane, including cofilin, profilin and
gelsolin, which then function to regulate actin dynamics and cell
motility [55]. In response to EGF, mammary adenocarcinoma cells
display increased actin nucleation within extending lamellipodia
through recruitment and activation of cofilin [56,57] in a PLCγ1
dependent manner [58,59].
PI3K, composed of regulatory (p85) and catalytic (p110)
subunits, binds to ErbB receptor family members, and functions
in growth factor signaling pathways crucial for proliferation and
migration. Inhibition of PI3K blocks EGF-induced DNA synthesis
[60]. Upon EGF stimulation, PIP3 levels are rapidly increased, with
a coordinate short-lived PI3K activation. Inhibition of Ras
attenuates the EGF-induced PIP3 production, as well as lamelli-
podia formation, suggesting that PI3K is downstream of Ras in the
process of EGF-mediated migration [61]. In breast cancer cells,
PI3K activity is required for HRG-mediated cell migration and
actin reorganization. Furthermore, PI3K is necessary for HRG-
induced p21-activated kinase 1 (PAK1) activity, as well as
formation of an ErbB2/actin/PAK1 signaling complex [62]. PAK1
controls several aspects of epithelial cell invasion, including stress
fiber formation, focal adhesion maintenance, MAPK and JNK
signaling cascades, and vascular endothelial growth factor (VEGF)
expression [63–65]. PAK1 regulates actin dynamics by phospho-
rylating LIM-kinase, which in turn phosphorylates cofilin, leading
to decreased depolymerization of F-actin [66]. PI3K signaling is
also required for EGF and HRG-mediated upregulation of
β1-integrin, an adhesion protein important for regulation of
epithelial cell polarity and implicated in tumor cell migration and
invasion [67]. Several small molecule PI3K inhibitors showing
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various solid tumors [68].
The non-receptor tyrosine kinase Src is overexpressed and
highly activated in a number of human cancers, including those of
the breast, lung and colon [69]. Although overexpression of Src
alone appears insufficient for tumor initiation, Src is required for
EGF-induced proliferation. Src directly interacts with the catalytic
domain of ErbB2 and ErbB2-induced mammary tumors show
increased levels of Src activation [70–72]. In a panel of human
colon cancer cell lines, ErbB1 and ErbB2-regulated Src activity was
associated with highly metastatic cell populations [73], suggestive
of a role for Src in the invasive phenotype. Inhibition of Src
kinase activity blocked invasion and lung metastasis of ErbB2-
overexpressing breast cancer cells, suggesting a role for Src in
ErbB2-mediated invasiveness [74]. In non-tumorigenic human
mammary epithelial cells grown in 3D culture, co-overexpression
of ErbB1 and Src induced aberrant proliferation and disrupted
polarity, leading to increased migration and invasion [75]. Several
downstream effectors of Src in response to ErbB activation have
been identified, including focal adhesion kinase (FAK) and protein
kinase C alpha (PKCα) [76,77]. FAK co-localizes with activated
ErbB2/3 receptors at cell protrusions, and is required for focal
adhesion complex formation, cell transformation and invasion. In
addition, FAK and ErbB2 are co-expressed in 50% of circulating
tumors cells in the peripheral blood from breast cancer patients,
suggesting a role for these proteins in migration and malignant
progression [78]. PKCα, a Src substrate, is required for ErbB2-
induced upregulation of urokinase-type plasminogen activator
receptor (uPAR) and cell invasion [79].
Several other cellular factors cooperate with ErbB receptors to
induce migratory and invasive phenotypes. A cDNA expression
screen for inducers of migration in growth-arrested 3D mammary
acini containing regulatable-ErbB2 uncovered transforming
growth factor β (TGF-β) as a mediator of invasion [80]. ErbB2
and TGF-β cooperate to activate extracellular signal-related kinase
(ERK), which is required for the migratory phenotype. Further-
more, mice co-expressing ErbB2 and TGF-β in the mammary
epithelium develop more lung metastasis than those expressing
ErbB2 alone, and TGF-β induces motility and invasiveness in an
ErbB2-dependent manner [81,82]. Recently, several specific ErbB2
phosphorylation events have been found to be required for TGF-
β-induced cancer cell invasion. These sites bind to the adaptor
protein ShcA. A dominant-negative ShcA molecule blocks migra-
tion and invasion induced by TGFβ; however, the signaling
pathway responsible for the cell movement downstream of ShcA
remains unclear [83].
Small G-proteins of the Ras superfamily regulate cell shape and
motility in response to extracellular signals. Upon EGF stimulation,
fibroblasts undergo Rho-dependent actin stress fiber reorganiza-
tion and Rac-dependent membrane ruffling [84,85]. Similarly,
Cdc42 is required for EGF-induced lamellipodia protrusion and
migration in breast cancer cells [86]. In A431 cells, EGF stimulates
an invasive phenotype dependent upon AP-1 transcription factor
activation. Inhibition of AP-1 activity blocks EGF-induced Rho and
Rac activation and cell motility [87]. EGF also induces Rac-
dependent migration through activation of MAPK and induction
of metalloproteinase ADAM10. ADAM10 cleaves the adhesion
molecule CD44, thereby increasing migratory ability of cells [88].
ErbB2 induces invasion in breast cancer cells by Rac-dependent
downregulation of α4 integrin [89]. Together, these results suggesta critical role for small G-proteins and cytoskeletal regulators in
the processes of migration and invasion.ErbB receptors, cell polarity and invasion
Changes in cellular cytoarchitecture have been strongly associated
with migration and invasion of cancer cells. For example, loss of
the epithelial state and acquisition of a mesenchymal phenotype
(through an epithelial–mesenchymal transition, EMT) is thought to
play a critical role during the processes of invasion and migration.
Changes in the normal apical–basal polarity of epithelial cells are
thought be necessary for the acquisition of a mesenchymal state.
Overexpression or activation of ErbB receptors has been shown to
disrupt normal polarity and lead to loss of cell–cell junctions in
epithelial cells. The precise mechanism by which ErbB receptors
deregulate normal epithelial architecture to promote invasion
remains to be understood. However, the relationship between ErbB
receptors and cell polarity signaling are beginning to be unraveled
in several model organisms, including Drosophila, C. elegans and
mammalian cells in culture.Molecular regulators of cell polarity
Cell polarity is a highly conserved evolutionary process. Genetic
analysis in Drosophila and C. elegans has identified several genes
that are involved in establishment and maintenance of apical–
basal polarity in epithelial cells. These determinants are conserved
in mammals and can be broadly grouped into three classes: the Par
complex, the Scribble complex and the Crumbs complex. The
Crumbs complex, containing Crumbs (Crb), PALS1 and PATJ, acts to
specify the apical domain, while the Scribble complex, consisting
of Scribble (Scr), Discs large (Dlg) and Lethal giant larvae (Lgl),
opposes the function of apical proteins to specify the basolateral
domain [90]. The Par complex consists of Par3, Par6 and atypical
protein kinase C (aPKC) and functions to establish andmaintain the
stability of the apical region and the apical–basal border [91]. The
aPKC activity associatedwith the Par complex plays a critical role in
defining the apical and basolateral domains. During the early
stages of the polarization process the kinase activity of aPKC is kept
low by its interaction with Par6, which in turn is bound to
members of apical and basolateral complexes such as Crb and Lgl.
As the polarization process continues, binding of Cdc42-GTP to
Par6 promotes activation of the Par6-associated aPKC kinase
activity and induces phosphorylation and release of the members
of the Crumbs and Scribble polarity complexes. For example, aPKC
phosphorylates Crb and directs Crb to the apical surface while
phosphorylation of Lgl results in release of Lgl from the apical
membrane and restricts it to the basal domain [91,92]. Release of
Lgl from the Par6 complex is accompanied by recruitment of Par3
to form the functional Par complex that defines the apical–lateral
border and the formation of tight junctions [91,92]. aPKC also
phosphorylates another serine/threonine kinase, Par1, to release it
from the apical–lateral border and localize it to the basolateral
membrane where it is thought to promote assembly of E-cadherin
junctions [92–94]. Par1 at the lateral membrane phosphorylates
Par3 and prevents its interaction with Par6/aPKC to restrict
assembly of the Par complex at the lateral membrane. Thus, the
scaffolding and kinase functions of the members of the polarity
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the Scr, Crb and Par protein complexes during establishment of
apical–basal polarity (Fig. 1). These processes are further coordi-
nated with changes in cytoskeletal reorganization, reorientation of
intracellular organelles and activation of small G-proteins, protein
kinases and phosphatases, resulting in diverse biological outcomes
during development. It is becoming clear that we have just begun
to scrape the surface in our understanding of the mechanisms that
regulate establishment of apical–basal polarity and there remains
much to be understood about the how polarity regulators interact
with each other and with the cell's cytoskeletal machinery.
In addition to their role in the establishment of apical–basal
polarity, polarity pathways have been strongly implicated in the
asymmetric cell division process and organ morphogenesis in C
elegans and Drosophila [95]. In mammals, polarity proteins are
known to regulate asymmetric cell division in T cells and cell
migration during neural tube closure and heart tube formation
[96,97]. The complex molecular mechanisms by which polarity
proteins signal to downstream effector molecules to establish and
maintain polarity during organogenesis in mammals is an area of
intense interest.Polarity proteins as regulators of cell migration
and invasion
Multiple lines of evidence in Drosophila suggest that inactivation of
polarity proteins can promote cancer formation and progression,
suggesting that polarity pathways can function as tumor suppres-
sors. Drosophila epithelia lacking Scr, Lgl or Dlg display increased
cell proliferation, in addition to loss of cellular organization [98].
However, when cells lacking Scr are surrounded by normal
epithelia, the ectopic cell proliferation induced by loss of ScrFig. 1 – Reciprocal interactions between polarity complexes
initiate and maintain apical–basal polarity in epithelial cells.
The Scribble complex consists of Scribble (Scr), Discs large (Dlg)
and Lethal giant larvae (Lgl). The Crumbs complex is made up of
Crumbs (Crb), Pals1 (Protein associated with lin-7) and
Pals1-associated tight junction protein (PATJ). The Par
(portioning defective) complex consists of Par3, Par6 and
atypical protein kinase C (aPKC).function is balanced by increased apoptosis through a Jun N-
terminal kinase (JNK)-dependent process. The increased cell death
is inhibited by coexpression of oncogenic Ras or Notch [99]
demonstrating a cooperation between polarity proteins and
oncogenes in regulating tumorigenesis in Drosophila. Similarly, a
screen designed to identify promoters of metastatic growth in a
noninvasive tumor model driven by activated Ras in Drosophila
detected numerous polarity proteins, including Scr, Dlg and Lgl
[100]. Recently, cooperation between Ras and Scr has been
demonstrated in mammalian cells, a process regulated by MAPK
signaling [101]. In humans, Scr and Dlg are targeted for degrada-
tion by the E6 oncoprotein of high-risk human papilloma virus,
suggesting that Scr and Dlg play a role in human papillomavirus
(HPV)-induced cervical cancer [102,103]. Most notably, several
polarity proteins show reduced expression in human cancers. In
colon neoplasias, expression of Scr and Dlg are downregulated in
regions of disrupted cell polarity and disorganized tissue archi-
tecture [104]. Expression of Hugl-1, the human homologue of Lgl, is
diminished in malignant melanoma, as well as solid tumors of the
breast, prostate, lung, ovary and colon [105–107]. Furthermore,
loss of Hugl-1 expression in endometrial cancer was shown to
correlate with increased lymph node metastasis as well as poor
clinical outcome [108]. Together, these observations strongly
suggest a role for polarity proteins during initiation and progres-
sion of cancer in humans.Polarity pathways as mediators of ErbB signaling
We recently demonstrated direct cooperation between members
of the ErbB family and polarity proteins during transformation of
polarized mammary epithelial cells. ErbB2 disrupts apical–basal
polarity and induces proliferation when activated in 3D mammary
acinar structures [109]. ErbB2 interacts with the Par6/aPKC
complex and this interaction is required for ErbB2-induced
disruption of polarity and inhibition of apoptosis. This interaction
is not required for ErbB2 induced cell proliferation. A detailed
investigation into the direct substrates of the Par6/aPKC complex
during ErbB2-induced disruption of 3D acini is likely to uncover
novel drug targets for treatment of ErbB2-positive breast cancers.
ErbB2-induced changes in polarity are also regulated by the β4
integrins. Tumor onset and metastatic progression of ErbB2-
induced tumors are delayed in mice lacking the intracellular
signaling domain of the β4 integrin. The β4 integrin promotes
ErbB2-driven mammary tumorigenesis through activation of the
transcription factors c-Jun and signal transducer and activator of
transcription 3 (STAT3) [110]. ErbB2 and β4 integrin cooperate by
recruiting the tyrosine kinase Src, which acts to phosphorylate
both proteins, enhancing ErbB2 kinase activity. Activation of the
ErbB2/β4 integrin complex promotes STAT3-dependent transcrip-
tion, which is required for disruption of cell polarity and the tight
junction complex.
ErbB1 directly regulates tight junction assembly through
phosphorylation of Par3 in a process requiring activation of the
tyrosine kinases Src and Yes [111]. Phosphorylation of Par3 disrupts
the Par3-LIM kinase 2 (LIMK2) interaction, allowing LIMK2 to
inactivate cofilin and promote tight junction assembly. In bladder
carcinoma cells, EGF stimulation creates a pool of free, uncom-
plexed tyrosine phosphorylated β-catenin that interacts less
strongly with E-cadherin, resulting in decreased cell–cell adhesion
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adhesion by inducing an epithelial–mesenchymal transition
through depletion of E-cadherin, both at the level of caveolin-
dependent endocytosis and Snail-mediated transcriptional repres-
sion [113]. The role polarity proteins play in ErbB-induced
migration and invasion is an underexplored area of investigation
that is likely to provide novel insights into how ErbB receptors
regulate metastatic disease.Polarity proteins as regulators of migration
and invasion
Studies in other signaling systems have identified polarity proteins
as critical regulators of migration and invasion. For example, TGF-β
induces disruption of tight junctions and EMT in NMuMG mouse
mammary epithelial cells [114] by interacting with the Par6
polarity complex. The type II TGF-β receptor phosphorylates
Par6, resulting in recruitment of the E3 ubiquitin ligase, Smurf1,
which in turn targets RhoA for proteasomal degradation and tight
junction disassembly. In rat proximal epithelial cells, TGF-β
induces disruption of apical–basal polarity by downregulating
Par3 [115] suggesting that TGF-β interacts with the Par complex in
multiple ways to disrupt cell polarity and promote migration.
The Par complex has also been shown to regulate astrocyte
migration [116]. Upon scratching through a monolayer culture,
astrocytes at the wound edge extend protrusions perpendicular to
the wound, reorient their microtubule cytoskeleton and Golgi, and
begin directed migration. This process involves the activation of
Cdc42, resulting in the recruitment of Par6 and aPKC to the leading
edge. The Par6/aPKC complex interacts directly with glycogenFig. 2 – ErbB receptor activation and overexpression disrupt mamm
pathways. ErbB-regulated cytoskeletal and adhesion signaling is me
kinase (PI3K), phospholipase Cγ (PLCγ), Src, focal adhesion kinase
molecular weight GTP-binding proteins Rho, Rac and Cdc42. Recen
through Par3, Par6 and LIM domain kinase 2 (LIMK2).synthase kinase 3β (GSK3β) to promote interaction of APC
(adenomatous polyposis coli) with the plus ends of microtubules
specifically at the leading edge [117] and regulate the polarity of
cell migration. APC in turn can recruit Dlg1 at discrete puncta
within the plasmamembrane to promotemicrotubule polarization
and cell migration [118]. In addition, Scr and the guanine
nucleotide exchange factor βPIX regulate migration of astrocytes
by promoting activation of Cdc42 at the leading edge [119]. The
precise relationship between the Scr, Dlg and Par complexes during
astrocyte migration remains to be understood.Conclusions and perspectives
Cancer pathologists have long noted the striking clinical correla-
tion between poorly differentiated primary tumors and less
favorable patient prognosis. Poorly differentiated tumors display
features including loss of glandular organization, loss of cell–cell
adhesion and loss of polarity. Although very little is known about
the processes underlying loss of polarity in human tumors,
accumulating evidence from several model systems has demons-
trated a role for regulation of cell polarity as a critical event during
migration and invasion. In addition to the known pathways that
control the cytoskeleton and cell adhesion, polarity pathways are
an emerging class of regulators of cancer cell biology that warrants
further study (Fig. 2). Detailed analysis into the mechanisms by
which oncogenes and tumor suppressors regulate mammalian
epithelial polarity is therefore a novel area of investigation that
will deepen our understanding of cancer biology and uncover
innovative paradigms for the development of strategies for
therapeutic intervention.alian epithelial polarity through known and emerging
diated by numerous proteins, including phosphatidylinositol 3
(FAK), mitogen activated protein kinase (MAPK), and the small
tly, ErbB receptors have been shown to disrupt cell polarity
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